Dr. Hortobagyi On Monaleesa-2 Trial Results In Breast Cancer

Dr. Hortobagyi on MONALEESA-2 Trial Results in Breast Cancer

Dr. Gabriel Hortobagyi on the Impact of MONALEESA-2 Trial in HR+ Breast Cancer

Results of the MONALEESA-2 Study in Advanced Breast Cancer

Targeted Oncology

ESMO 2016: Press brief on the MONALEESA-2 clinical trial on breast cancer

Dr. Burris on Updated MONALEESA-2 Trial Results for HR+ Breast Cancer

Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

Targeted Oncology

Gabriel Hortobagyi:

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozole

Dr. Hortobagyi Discusses the BOLERO-2 Trial

QOL in MONALEESA-2, 3, and 7

Safety and efficacy of ribociclib and letrozole in advanced breast cancer – the MONALEESA-2 trial

Dr. Slamon the Phase III Results of MONALEESA-3 Trial in HR+/HER2- Breast Cancer

Gabriel N. Hortobagyi, et al.

Dr. Gabriel Hortobagyi remarks; overview of targeted therapies, hormonal therapy

Breast Cancer Research Foundation

MONALEESA-7 Trial in Premenopausal HR+ Breast Cancer

Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...

MONALEESA-3: Ribociclib Plus Fulvestrant in HR+ mBC

Practical Implications of the MONALEESA-3 Trial

Targeted Oncology

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence

Gabriel N. Hortobagyi, MD, FACP

Breast Cancer Research Foundation